APA

Kimijima I., Tominaga T., Nomizu T., Nomura Y., Takashima S., Koyama H., Sano M., Tohge T., Ueo H., Ikeda S. & Ohashi Y. (20020611). [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]. : Gan to kagaku ryoho. Cancer & chemotherapy.

Chicago

Kimijima Izo, Tominaga Takeshi, Nomizu Tadashi, Nomura Yasuo, Takashima Shigemitsu, Koyama Hiroki, Sano Muneaki, Tohge Tetsuya, Ueo Hiroaki, Ikeda Seiyo and Ohashi Yasuo. 20020611. [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]. : Gan to kagaku ryoho. Cancer & chemotherapy.

Harvard

Kimijima I., Tominaga T., Nomizu T., Nomura Y., Takashima S., Koyama H., Sano M., Tohge T., Ueo H., Ikeda S. and Ohashi Y. (20020611). [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]. : Gan to kagaku ryoho. Cancer & chemotherapy.

MLA

Kimijima Izo, Tominaga Takeshi, Nomizu Tadashi, Nomura Yasuo, Takashima Shigemitsu, Koyama Hiroki, Sano Muneaki, Tohge Tetsuya, Ueo Hiroaki, Ikeda Seiyo and Ohashi Yasuo. [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]. : Gan to kagaku ryoho. Cancer & chemotherapy. 20020611.